• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Silence Therapeutics Plc - American Depository Share (NQ:SLN)

    7.646 +0.296 (+4.03%)
    Streaming Delayed Price Updated: 9:32 AM EDT, Mar 17, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Silence Therapeutics Plc - American Depository Share

    < Previous 1 2 3 4 5 6 Next >
    News headline image
    Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
    From Silence Therapeutics plc
    Via Business Wire
    News headline image
    Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)
    From Silence Therapeutics plc
    Via Business Wire
    News headline image
    Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024
    From Silence Therapeutics plc
    Via Business Wire
    News headline image
    Where Silence Therapeutics Stands With Analysts ↗
     
    Via Benzinga
    News headline image
    What 6 Analyst Ratings Have To Say About Silence Therapeutics ↗
     
    Via Benzinga
    News headline image
    The Latest Analyst Ratings for Silence Therapeutics ↗
     
    Via Benzinga
    News headline image
    Earnings Scheduled For March 13, 2024 ↗
    Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million. 
    Via Benzinga
    News headline image
    Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial
    From Silence Therapeutics plc
    Via Business Wire
    News headline image
    Earnings Scheduled For March 12, 2024 ↗
    Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is likely to report earnings for its fourth quarter. 
    Via Benzinga
    News headline image
    Silence Therapeutics Announces Oversubscribed $120 Million Private Placement
    From Silence Therapeutics plc
    Via Business Wire
    News headline image
    Boeing Posts Upbeat Results, Joins Stryker, Automatic Data Processing And Other Big Stocks Moving Higher On Wednesday ↗
    U.S. stocks traded mostly lower, with the Nasdaq Composite falling over 200 points on Wednesday. 
    Via Benzinga
    Topics Stocks
    News headline image
    Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
    From Silence Therapeutics plc
    Via Business Wire
    News headline image
    12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
     
    Via Benzinga
    News headline image
    Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments
    From Silence Therapeutics plc
    Via Business Wire
    News headline image
    Silence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results
    From Silence Therapeutics plc
    Via Business Wire
    News headline image
    Silence Therapeutics to Present at Jefferies London Healthcare Conference
    From Silence Therapeutics plc
    Via Business Wire
    News headline image
    Is This A Miracle Drug For 'Sticky Cholesterol'? Analysts Applaud Safety, Efficacy Of Silence Therapeutics' Heart Disease Candidate ↗
    Earlier today, Silence Therapeutics plc (NASDAQ: SLN) announced topline results from the multiple-dose component of the APOLLO phase 1 study of zerlasiran (formerly SLN360) in 36 adults with baseline... 
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
     
    Via Benzinga
    News headline image
    Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease
    From Silence Therapeutics plc
    Via Business Wire
    News headline image
    Silence Therapeutics to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference
    From Silence Therapeutics plc
    Via Business Wire
    News headline image
    Silence Therapeutics to Participate in September Investor Conferences
    From Silence Therapeutics plc
    Via Business Wire
    News headline image
    Silence Therapeutics Reports Second Quarter 2023 Results
    From Silence Therapeutics plc
    Via Business Wire
    News headline image
    Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration
    From Silence Therapeutics plc
    Via Business Wire
    News headline image
    Earnings Scheduled For August 10, 2023 ↗
    Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million. 
    Via Benzinga
    News headline image
    Silence Therapeutics to Present at the Jefferies Healthcare Conference
    From Silence Therapeutics plc
    Via Business Wire
    News headline image
    Silence Therapeutics Reports First Quarter 2023 Results
    From Silence Therapeutics plc
    Via Business Wire
    News headline image
    Benzinga's Top Ratings Upgrades, Downgrades For May 8, 2023 ↗
     
    Via Benzinga
    News headline image
    Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration
    From Silence Therapeutics plc
    Via Business Wire
    News headline image
    Silence Therapeutics Completes Enrollment in Phase 2 Study of Zerlasiran (SLN360) in Subjects with Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events
    From Silence Therapeutics plc
    Via Business Wire
    News headline image
    Stocks That Hit 52-Week Lows On Tuesday ↗
      Tuesday's session saw 286 companies set new 52-week lows. 
    Via Benzinga
    < Previous 1 2 3 4 5 6 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.